lymphocytic leukemia

Summary

Summary: Leukemia associated with hyperplasia and overactivity of the lymphoid tissue. There are increased numbers of circulating malignant lymphocytes and lymphoblasts. (Dorland, 28th ed, p919)

Top Publications

  1. ncbi A review of large granular lymphocytic leukemia in Fischer 344 rats as an initial step toward evaluating the implication of the endpoint to human cancer risk assessment
    Johnson Thomas
    Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan 48674, USA
    Toxicol Sci 99:3-19. 2007
  2. ncbi In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells
    M A Mosaddik
    Centre for Phytochemistry, Southern Cross University, Lismore, NSW, Australia
    Phytomedicine 10:682-5. 2003
  3. ncbi The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
    Ross L Levine
    Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
    Blood 106:3377-9. 2005
  4. ncbi Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity
    Roberto P Falcão
    Department of Clinical Medicine, School of Medicine Ribeirão Preto USP, Ribeirao Preto, SP, Brazil
    Leuk Res 26:803-7. 2002
  5. ncbi A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia
    Tsieh Sun
    Pathology and Laboratory Medicine Service, Veterans Affairs Medical Center, Denver, CO, 80220, USA
    Hum Pathol 34:504-8. 2003
  6. ncbi Effects of interferon gamma on native human acute myelogenous leukaemia cells
    Elisabeth Ersvaer
    Institute of Medicine, Section for Hematology, The University of Bergen and Haukeland University Hospital, Bergen, Norway
    Cancer Immunol Immunother 56:13-24. 2007
  7. ncbi Aggressive natural killer cell lymphoma/leukemia
    Po Shing Lee
    Department of Pathology, Chi Mei Foundation Medical Center, Tainan, Taiwan, ROC
    Zhonghua Yi Xue Za Zhi (Taipei) 65:622-6. 2002
  8. ncbi Establishment of the T-cell large granular lymphocyte leukemia cell line MOTN-1 carrying natural killer-cell antigens
    Yoshinobu Matsuo
    Fujisaki Cell Center, Hayashibara Biochemical Laboratories Inc, 675 1 Fujisaki, Okayama, Japan
    Leuk Res 26:873-9. 2002
  9. ncbi Masked MLL gene rearrangement was disclosed in the clinical course and sequential development of chromosome abnormality in a patient with therapy related acute myelogenous leukemia
    Shigeo Hashimoto
    First Department of Internal Medicine, Faculty of Medicine, Niigata University Medical Hospital, Niigata, Japan
    Leuk Res 27:285-90. 2003
  10. ncbi Heparanase expression in human leukemias is restricted to acute myeloid leukemias
    Menachem Bitan
    Department of Pediatrics, Hadassah-Hebrew University Hospital, Jerusalem, Israel
    Exp Hematol 30:34-41. 2002

Research Grants

  1. Post-transplant vaccines to enhance graft-versus-leukemia responses
    CATHERINE JU YING WU; Fiscal Year: 2010
  2. Long-term Effects of Occupational Radiation Exposures
    David Richardson; Fiscal Year: 2009
  3. ADENINE DEOXYNUCLEOTIDE METABOLISM AND IMMUNE FUNCTION
    Dennis Carson; Fiscal Year: 1993
  4. Long-term Effects of Occupational Radiation Exposures
    David B Richardson; Fiscal Year: 2010
  5. Preclinical Diagnostic Imaging of Amyloid
    Jonathan S Wall; Fiscal Year: 2010
  6. Preclinical Diagnostic Imaging of Amyloid
    Jonathan Wall; Fiscal Year: 2009
  7. HUMAN IL3 ACTIVATION OF PROTEIN KINASE C AND BCL-2 GENE
    Yufang Shi; Fiscal Year: 2001
  8. Assays for Screening Histone Modifications in Cancer
    Michael A Freitas; Fiscal Year: 2010
  9. Modulation of Glucocorticoid-Evoked Lymphocyte Apoptosis by BTG1
    RHEEM MEDH; Fiscal Year: 2007
  10. Genomic Complexity and Clinical Outcome in Chronic Lymphocytic Leukemia
    SAMI NIMER MALEK; Fiscal Year: 2010

Detail Information

Publications186 found, 100 shown here

  1. ncbi A review of large granular lymphocytic leukemia in Fischer 344 rats as an initial step toward evaluating the implication of the endpoint to human cancer risk assessment
    Johnson Thomas
    Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan 48674, USA
    Toxicol Sci 99:3-19. 2007
    ..Thus, it was concluded that the evaluation of possible chemically related increases in rat LGLL utilize a "weight-of-evidence" approach...
  2. ncbi In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells
    M A Mosaddik
    Centre for Phytochemistry, Southern Cross University, Lismore, NSW, Australia
    Phytomedicine 10:682-5. 2003
    ..isolated from the dried root of Salvia miltiorrhiza Bunge (Lamiaceae) were studied in vitro using P388 lymphocytic leukemia cells. Tanshinone I and tanshinone IIA were shown to be quite strongly cytotoxic against the cells (86...
  3. ncbi The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
    Ross L Levine
    Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
    Blood 106:3377-9. 2005
    ..myelodysplastic syndrome (MDS), B-lineage acute lymphoblastic leukemia (ALL), T-cell ALL, and chronic lymphocytic leukemia (CLL)...
  4. ncbi Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity
    Roberto P Falcão
    Department of Clinical Medicine, School of Medicine Ribeirão Preto USP, Ribeirao Preto, SP, Brazil
    Leuk Res 26:803-7. 2002
    ..NK cell activity was demonstrated only in one out of the two cases tested. The negative reactions with alpha-naphthyl-acetate-esterase (ANAE), CD11b and CD14 strongly suggested that the tumor cells were not of the monocytic lineage...
  5. ncbi A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia
    Tsieh Sun
    Pathology and Laboratory Medicine Service, Veterans Affairs Medical Center, Denver, CO, 80220, USA
    Hum Pathol 34:504-8. 2003
    ..The clinical implications of these findings are discussed...
  6. ncbi Effects of interferon gamma on native human acute myelogenous leukaemia cells
    Elisabeth Ersvaer
    Institute of Medicine, Section for Hematology, The University of Bergen and Haukeland University Hospital, Bergen, Norway
    Cancer Immunol Immunother 56:13-24. 2007
    ..We conclude that IFNgamma can be released in the presence of native human AML cells and affect AML cell proliferation, regulation of apoptosis and the balance between pro- and antiangiogenic chemokine release...
  7. ncbi Aggressive natural killer cell lymphoma/leukemia
    Po Shing Lee
    Department of Pathology, Chi Mei Foundation Medical Center, Tainan, Taiwan, ROC
    Zhonghua Yi Xue Za Zhi (Taipei) 65:622-6. 2002
    ..In situ hybridization for Epstein-Barr virus (EBV)-associated RNA (EBER) was positive. Various forms of NK cell neoplasm were reviewed and discussed...
  8. ncbi Establishment of the T-cell large granular lymphocyte leukemia cell line MOTN-1 carrying natural killer-cell antigens
    Yoshinobu Matsuo
    Fujisaki Cell Center, Hayashibara Biochemical Laboratories Inc, 675 1 Fujisaki, Okayama, Japan
    Leuk Res 26:873-9. 2002
    ..The scientific significance of MOTN-1 lies in (1) the rarity of this type of leukemia cell lines, (2) the co-expression of various T- and natural killer (NK)-cell-associated markers, and (3) its unique chromosomal aberrations...
  9. ncbi Masked MLL gene rearrangement was disclosed in the clinical course and sequential development of chromosome abnormality in a patient with therapy related acute myelogenous leukemia
    Shigeo Hashimoto
    First Department of Internal Medicine, Faculty of Medicine, Niigata University Medical Hospital, Niigata, Japan
    Leuk Res 27:285-90. 2003
    ..Like this situation, a masked MLL rearrangement may have existed in some cases with hematopoietic malignancies, and appear to be disclosed in the clinical course...
  10. ncbi Heparanase expression in human leukemias is restricted to acute myeloid leukemias
    Menachem Bitan
    Department of Pediatrics, Hadassah-Hebrew University Hospital, Jerusalem, Israel
    Exp Hematol 30:34-41. 2002
    ..CONCLUSION: We propose that heparanase expression is associated with the myeloid lineage and may serve as an independent marker to support the identification of AMLs...
  11. ncbi T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years
    Ahmed Aribi
    Department of Leukemia, Unit 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 31:939-45. 2007
    ..Significant responses were not seen with any of these treatment regimens. We conclude that cyclosporine therapy may be beneficial for T-LGL leukemia patients. New treatment modalities are needed for these patients...
  12. ncbi Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
    Syed Rehan A Hussain
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 13:2144-50. 2007
    ..Mcl-1 has also been reported to mediate resistance to rituximab in CLL. We therefore investigated whether direct reduction of Mcl-1 was sufficient to induce apoptosis and increase sensitivity to rituximab...
  13. ncbi The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate
    Simona Gatto
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Haematologica 88:853-63. 2003
    ..The use of PS-341 should be explored in patients with chronic myelogenous leukemia resistant to IM. Trials of combinations of PS-341 and IM require cautious design...
  14. ncbi Challenge in diagnosis of CD56+ lymphoproliferative disorders: two cases of CD56+CD33+ lymphoma/leukemia
    Xu Yang
    Department of Pathology, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    Arch Pathol Lab Med 128:e100-3. 2004
    ..Both disorders are aggressive hematopoietic malignancies that have similar clinical presentation and morphology but differ in immunophenotype and cytogenetic features...
  15. ncbi Disruption of mitochondrial membrane potential during apoptosis induced by PSC 833 and CsA in multidrug-resistant lymphoid leukemia
    Juanita Bustamante
    Catedra de Fisicoquimica, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, 1113 Buenos Aires, Argentina
    Toxicol Appl Pharmacol 199:44-51. 2004
    ..This is mediated through mitochondrial events, associated with an evident decrease in DeltaPsi(m), cytochrome c release and caspase 3 activation...
  16. ncbi Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis
    K Stahnke
    University Children's Hospital, Ulm. Germany
    Apoptosis 9:457-65. 2004
    ..Flow cytometric analysis of mitochondrial apoptosis signaling may provide a useful tool for the prediction of drug resistance and treatment failure in primary leukemia...
  17. ncbi Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy
    Brian D Lichty
    Ottawa Regional Cancer Centre Research Laboratories, Ottawa, Ontario, Canada K1H 1C4
    Hum Gene Ther 15:821-31. 2004
    ..This study demonstrates the potential utility of VSV in the treatment, both ex vivo and in vivo, of hematologic malignancies...
  18. ncbi Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)
    Daniela Pende
    Istituto Nazionale per la Ricerca sul Cancro, L go R Benzi 10, 16132 Genova, Italy
    Blood 105:2066-73. 2005
    ..In most leukemias, both CD48 and NTBA were down-regulated. The correlation found between marker expression and susceptibility to lysis may reveal useful information for NK-based immunotherapy...
  19. ncbi CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab
    N Osuji
    Section of Haemato-Oncology, Royal Marsden NHS Trust and Institute of Cancer Research, London, UK
    Leuk Lymphoma 46:723-7. 2005
    ..Higher CD52 expression has been noted in responders to alemtuzumab in T-cell PLL and in chronic lymphocytic leukemia (CLL), a B-cell disorder...
  20. ncbi Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells
    R Suzuki
    Division of Molecular Medicine, Aichi Cancer Center, Nagoya, Japan
    Leukemia 18:763-70. 2004
    ..005). These findings suggest that ANKL is an entity of mature cytotoxic NK-cell neoplasms with distinct phenotype and disease presentations. Intensive treatment for ANKL may result in a better prognosis...
  21. ncbi [Expression of Pin1 in malignant hematopoietic cells and its relation with cell cycle]
    Yuan-Yuan Zhu
    The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
    Zhejiang Da Xue Xue Bao Yi Xue Ban 33:500-3, 514. 2004
    ..762 +/-16.737 compared with 4.080 +/-0.634, P<0.01). CONCLUSION: Pin1 is overexpressed in malignant hematopoietic cell lines and its expression is different during cell cycle that is highest in G1 phase and lowest in S phase...
  22. ncbi Induction of apoptosis in lymphoid and myeloid leukemia
    Aaron D Schimmer
    Princess Margaret Hospital, Room 9 516, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
    Curr Oncol Rep 8:430-6. 2006
    ..This review highlights compounds that target the mitochondrial, death receptor, and convergence pathways of caspase activation that are being developed for the treatment of acute leukemia...
  23. ncbi [Clinical evaluation of biapenem for febrile neutropenia in patients with hematological disorders]
    Hirotaka Sakai
    Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital
    Jpn J Antibiot 60:125-31. 2007
    ..The underlying diseases were acute myelogenous leukemia in 16 cases, acute lymphocytic leukemia in 1, malignant lymphoma in 14, myelodysplastic syndrome in 1, aplastic anemia in 1...
  24. ncbi [Update on malignant hemopathies]
    Valerie Ugo
    Departement d Hematologie et d Oncologie Medicale, Hotel Dieu, 75181 Paris Cedex 04 et Inserm EMI9912 EA1529, Paris 6
    Bull Cancer 89:75-88. 2002
    ..The other side of these molecules is their incredibly high cost, explaining the uncontrolled expenses in 2001 of hospitals hosting hematology as well as oncology activities...
  25. ncbi [Analysis of CD117 expression on leukemia cells]
    Hong-qiang Shen
    Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
    Zhonghua Xue Ye Xue Za Zhi 24:228-30. 2003
    ..CD(117) was negative in CML in chronic phase and chronic lymphocytic leukemia. Cases in AML, CD(117) was expressed in 72% of M(0)/M(1), 88% of M(2), 50% of M(4), 75% of M(5a), 100% of M(..
  26. ncbi In vitro studies on the toxicity of isoniazid in different cell lines
    Christina E Schwab
    ARC Seibersdorf Research GmbH, Department Toxicology, A-2444 Seibersdorf, Austria
    Hum Exp Toxicol 22:607-15. 2003
    ..Thus the present study unequivocally demonstrated that INH induces cytotoxicity via apoptosis and can lead to a significant disturbance of the cell cycle in mammalian cells...
  27. ncbi Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence
    Suchitra Acharya
    Department of Pediatrics, New York Presbyterian Hospital and Cornell-Weil Medical School, New York, New York, USA
    Cancer 97:2397-403. 2003
    ..Because thyroid neoplasms may not become evident for decades after radiation therapy, all individuals who are at risk require life-long follow-up...
  28. ncbi Lymphohematopoietic cancers in the United Farm Workers of America (UFW), 1988-2001
    Paul K Mills
    Cancer Registry of Central California Public Health Institute, 1320 E Shaw Avenue, Suite 160, Fresno, CA 93710, USA
    Cancer Causes Control 16:823-30. 2005
    ..Agricultural risk factors for lymphohematopoietic cancers (LHC) in Hispanic farm workers in California were examined in a nested case-control study embedded in a cohort of 139,000 ever members of a farm worker labor union in California...
  29. ncbi Haematological malignancies in childhood in Croatia: investigating the theories of depleted uranium, chemical plant damage and 'population mixing'
    B Labar
    Faculty of Medicine, University of Zagreb, Croatia
    Eur J Epidemiol 19:55-60. 2004
    ..In those counties, the incidence of Hodgkin's lymphoma decreased during and after the war. In Croatia as a whole, decreases in incidence of myeloid leukaemias during war and non-Hodgkin lymphoma after the war were noted...
  30. ncbi Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:656-64. 2002
    ..To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia...
  31. ncbi Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy
    T Mardesic
    Sonatorium Pronatal, Prague, Czech Republic
    Eur J Gynaecol Oncol 25:90-2. 2004
    ..CONCLUSIONS: The combination of GnRH-agonist and GnRH-antagonist enables a rapid, reliable and cost-effective suppression of the pituitary-gonadal axis to be achieved. Future gonadal function of treated patients will be monitored...
  32. ncbi 4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramide-induced mitochondrial oxidative stress and is regulated downstream by Bcl-2
    Maria Celia Morales
    Department of Cell Biology and Histology, Faculty of Medicine and Dentistry, University of the Basque Country, Barrio Sarriena s n, Leioa, Bizkaia, Spain
    Free Radic Res 41:591-601. 2007
    ....
  33. ncbi 2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia
    Panagiotis Tsirigotis
    Third Department of Internal Medicine, First Hospital of Athens, Social Insurance Foundation, Zaimi Street Melissia, 15127 Athens, Greece
    Leuk Res 27:865-7. 2003
    ..Flow cytometric analysis of TCR-Vbeta repertoire proved to be an effective method to assess the therapeutic response to various treatments and to evaluate residual disease...
  34. ncbi Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
    Robert J McKallip
    Department of Microbiology and Immunology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
    Blood 100:627-34. 2002
    ..Also, because CB2 agonists lack psychotropic effects, they may serve as novel anticancer agents to selectively target and kill tumors of immune origin...
  35. ncbi Cyanidin 3-O-beta-D-glucoside isolated from skin of black Glycine max and other anthocyanins isolated from skin of red grape induce apoptosis in human lymphoid leukemia Molt 4B cells
    Hirotaka Katsuzaki
    Faculty of Bioresources, Mie University, Mie 514-0001, Japan
    Oncol Rep 10:297-300. 2003
    ..These findings suggest that growth inhibition of Molt 4B cells by these anthocyanins result from the induction of apoptosis by these compounds and that active oxygen is involved in the induction of apoptosis in the Molt 4B cells...
  36. ncbi Diol- and triol-types of phytol induce apoptosis in lymphoid leukemia Molt 4B cells
    Hiroshige Hibasami
    Faculty of Medicine, Mie University, Tsu-city, Mie 514-0001, Japan
    Int J Mol Med 10:555-9. 2002
    ..These findings suggest that growth inhibition of Molt 4B cells by the diol- and triol-types of phytol results from the induction of apoptosis in the leukemic cells...
  37. ncbi Mature T-cell leukemias
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1808-18. 2005
    ..Herein, we review the clinical and pathological features of mature T-cell leukemias...
  38. ncbi Cell division rates of primary human precursor B cells in culture reflect in vivo rates
    Jonathan Cooperman
    Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Stem Cells 22:1111-20. 2004
    ..These findings indicate that the stroma-based cultures faithfully replicate in vivo cell division rates and can be used to elucidate the pathways that regulate cell division of primary human precursor B cells...
  39. ncbi Influence of altered apoptosis in human lymphoblastoid cell lines on micronucleus frequency
    Vladimir Vukicevic
    Department of Toxicology, , , Germany
    Toxicol Lett 147:187-95. 2004
    ..When apoptosis was increased, micronucleus formation remained unchanged or was also increased. Overall, we did not find an expected inverse correlation between induction of apoptosis and genomic damage...
  40. ncbi Octylcaffeate induced apoptosis in human leukemia U937 cells
    Mayuko Ujibe
    Department of Pharmacology and Toxicology, Cancer Research Institute, Tohoku Pharmaceutical University, Sendai 981-8558, Japan
    Biol Pharm Bull 28:2338-41. 2005
    ..These findings suggest that the cytotoxicity of octylcaffeate involves the induction of apoptosis...
  41. ncbi The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines
    Kai Uwe Chow
    Department of Medicine II, Hematology and Oncology, Johann Wolfgang Goethe University Hospital Frankfurt am Main, Germany
    Leuk Lymphoma 48:1379-88. 2007
    ..In conclusion, this is the first report providing evidence that activity of AMN107 is not restricted to Bcr-Abl, c-Kit, or PDGFR-positive cells, but also extends to lymphatic cell lines of B-cell origin...
  42. ncbi Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement
    Ritsuro Suzuki
    Division of Molecular Medicine, Aichi Cancer Center, Nagoya, Japan
    Cancer 104:1022-31. 2005
    ..Although further investigations are needed to settle a marker for distinction, the presence of cutaneous involvement is a useful prognostic factor...
  43. ncbi Clinical features in T-cell vs. natural killer-cell variants of large granular lymphocyte leukemia
    Michelle A Neben
    Division of Hematology and Internal Medicine; Division of Hematopathology, Mayo Clinic, Mayo Medical School, Rochester, MN 55905, USA
    Eur J Haematol 71:263-5. 2003
    ..04) and a higher frequency of palpable splenomegaly (P < 0.01). CONCLUSION: Overall disease progression and response to immunosuppressive therapy are similar between T-cell and natural killer-cell variants of LGLL...
  44. ncbi Blastic natural killer (NK) cell leukemia (agranular CD4+CD56+ leukemia)
    Kai Zhang
    Division of Laboratory Medicine, Geisinger Medical Center, Danville, PA 17822 0131, USA
    Ann Clin Lab Sci 36:212-5. 2006
    ..Blastic NK cell lymphoma is a rare hematolymphoid neoplasm. This report illustrates an unusual presentation of this entity, namely as a primary leukemia, but without skin lesions...
  45. ncbi A case of clinical indolent natural killer cell lineage large granular lymphocytic leukemia in a patient with rheumatoid arthritis
    J N Machatschek
    Department of Haematology, Peter MacCallum Cancer Institute, St. Andrew's Place, East Melbourne, VIC 3002, Australia
    Leuk Lymphoma 44:1223-7. 2003
    ..5 months. This case illustrates previously unrecognized heterogeneity in the natural history of this disorder...
  46. ncbi Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes
    R C Burnett
    Department of Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
    Vet Pathol 40:32-41. 2003
    ....
  47. ncbi Molecular methods to distinguish reactive and neoplastic lymphocyte expansions and their importance in transitional neoplastic states
    Paul R Avery
    Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Fort Collins, CO 80523, USA
    Vet Clin Pathol 33:196-207. 2004
    ....
  48. ncbi Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells
    Silvia Deaglio
    Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, University of Torino Medical School, Via Santena 19, Turin, Italy
    Blood 99:2490-8. 2002
    ..This molecule is CD16 in NK cells...
  49. ncbi The small oligomerization domain of gephyrin converts MLL to an oncogene
    Mariko Eguchi
    Leukaemia Research Fund Centre, Institute of Cancer Research, Chester Beatty Laboratories, London, United Kingdom
    Blood 103:3876-82. 2004
    ..Our results, and other recent data, provide a mechanism for oncogenic conversion of MLL by fusion partners encoding cytoplasmic proteins...
  50. ncbi Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis
    Lesley F Drynan
    MRC Laboratory of Molecular Biology, Cambridge, UK
    EMBO J 24:3136-46. 2005
    ..Therefore, a permissive cellular environment is required for oncogenicity of Mll-associated translocations and Mll fusions can influence haematopoietic lineage commitment...
  51. ncbi The viral envelope is a major determinant for the induction of lymphoid and myeloid tumours by avian leukosis virus subgroups A and J, respectively
    P M Chesters
    Viral Oncogenesis Group, Institute for Animal Health, Compton, Berkshire RG20 7NN, UK
    J Gen Virol 83:2553-61. 2002
    ..Induction of both LL and ML by the two chimeric viruses occurred through the activation of c-myc, while the EB tumours were induced by activation of the c-erbB oncogene...
  52. ncbi Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial
    M Gomez-Nunez
    Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Bone Marrow Transplant 33:477-82. 2004
    ..However, age by itself should not preclude these RIC transplants, since TRM appears to be unacceptably high only in the presence of additional adverse factors...
  53. ncbi Activation of c-myb by 5' retrovirus promoter insertion in myeloid neoplasms is dependent upon an intact alternative splice donor site (SD') in gag
    Jean Marie Ramirez
    , CNRS UMR5121, UMI, IFR122, Montpellier, France
    Virology 330:398-407. 2004
    ..Importantly, there was a complete lack of myeloid tumors associated with 5' insertional mutagenic activation of c-myb, suggesting the specific requirement of the SD' site in this mechanism...
  54. ncbi Clinical and imaging characteristics of orbital leukemic tumors
    Maziar Bidar
    Department of Surgery, Division of Ophthalmology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Ophthal Plast Reconstr Surg 23:87-93. 2007
    ..To characterize the clinical and imaging features of orbital leukemic tumors in 27 patients seen and treated at St. Jude Children's Research Hospital...
  55. ncbi Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias
    H M Amin
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Leukemia 19:1567-72. 2005
    ..These data also suggest that MDS classification schemes should take into account the percentage of blasts in PB differently from the percentage of blasts in BM...
  56. ncbi 1,3-Butadiene and leukemia among synthetic rubber industry workers: exposure-response relationships
    Hong Cheng
    University of Alabama at Birmingham, Ryals School of Public Health, Department of Epidemiology, Birmingham, AL, USA
    Chem Biol Interact 166:15-24. 2007
    ..The present results support the presence of a causal relationship between high cumulative exposure and high intensity of exposure to BD and leukemia...
  57. ncbi Human leucocyte antigen-Cw-specific cytotoxic T lymphocytes generated from naive cord blood used for cord blood stem cell transplantation
    Makoto Yazaki
    Department of Paediatrics, Nagoya City University Medical School, 1 Kawasumi, Mizuho cho, Nagoya 467 8601, Japan
    Br J Haematol 117:893-8. 2002
    ....
  58. ncbi Flow cytometry in the diagnosis of mediastinal tumors with emphasis on differentiating thymocytes from precursor T-lymphoblastic lymphoma/leukemia
    Wojciech Gorczyca
    Division of Hematopathology, IMPATH Inc, 521 West 57th Street, New York, NY 10019, USA
    Leuk Lymphoma 45:529-38. 2004
    ..In experienced hands, flow cytometry plays a valuable and complementary role to histology and immunohistochemistry in diagnosing mediastinal tumors...
  59. ncbi [Disseminated fusarium infection in two neutropenic children]
    A Petit
    , , , France
    Arch Pediatr 12:1116-9. 2005
    ..CONCLUSION: Voriconazole, a new triazole agent, seems to be an alternative antifungal agent to amphotericin B for disseminated fusarium infection, either at the acute phase or for secondary prophylaxis...
  60. ncbi Preimplantation HLA testing
    Yury Verlinsky
    Reproductive Genetics Institute, Chicago, Ill 60657, USA
    JAMA 291:2079-85. 2004
    ....
  61. ncbi [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases]
    Ika Kardum-Skelin
    Klinicka bolnica Merkur, Zagreb, Hrvatska
    Acta Med Croatica 62:351-64. 2008
    ..The aim of the study was to identify the clinical and laboratory (hematologic, biochemical and morphological) prognostic parameters of chronic leukemic lymphoproliferative diseases (CLLPD)...
  62. ncbi Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination
    S Rutella
    Department of Hematology, Center for the Flow Cytometric Study of Blood Cells, Catholic University, Largo A Gemelli 8, 00168 Rome, Italy
    Haematologica 84:419-24. 1999
    ..We investigated the expression of CD36 in B-cell chronic lymphocytic leukemia (CLL) by multiparameter flow cytometry; results were correlated with clinical features.
  63. ncbi Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma†
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 25:55-61. 2011
    ..This article reviews the use of intravenous rituximab in the treatment of chronic lymphocytic leukemia (CLL), low-grade or follicular lymphoma, and diffuse large B-cell lymphoma...
  64. ncbi Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
    Patricia Aoun
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198 3135, USA
    Leuk Lymphoma 45:1595-603. 2004
    Routine cytogenetic analysis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) frequently fails to identify an abnormal clone due to the low rate of spontaneous mitoses and poor response to mitogen stimulation...
  65. ncbi Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma
    Trevor W Dennie
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Clin Ther 31:2290-311. 2009
    ..Bendamustine was approved by the US Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) in March 2008 and for the treatment of rituximab-refractory, indolent B-cell non-Hodgkin lymphoma (..
  66. ncbi Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation
    Lucia Farina
    Division of Hematology Bone Marrow Transplantation, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milan, Italy
    Haematologica 94:654-62. 2009
    The graft-versus-leukemia effect is able to induce clinical responses in patients with chronic lymphocytic leukemia treated with a reduced intensity conditioning regimen, followed by allogeneic stem cell transplantation...
  67. ncbi [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]
    Jia Yu Ling
    State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 26:418-22. 2007
    Diagnosis of lymphocytic leukemia and non-Hodgkin's lymphoma (NHL) is based on bone marrow morphology...
  68. ncbi Detection of chromosomal abnormalities in chronic lymphocytic leukemia increased by interphase fluorescence in situ hybridization in tetradecanoylphorbol acetate-stimulated peripheral blood cells
    Jana Sanchez
    Department of Hematology, Hospital Sant Pau, Autonomous University of Barcelona, Avda Sant Antoni M a Claret 167, 08025 Barcelona, Spain
    Cancer Genet Cytogenet 175:57-60. 2007
    ..is used to detect chromosomal abnormalities such as 11q-, 13q-, 17p-, and trisomy 12 in chronic lymphocytic leukemia (CLL)...
  69. ncbi In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia
    Mario De Decker
    Department of Radiopharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
    Nucl Med Biol 35:599-604. 2008
    ..It is being developed for the treatment of chronic lymphocytic leukemia (CLL), autoimmune disease and for the prevention of transplant rejection...
  70. ncbi Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia
    Mark A Weiss
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 21:1278-84. 2003
    Purine analogs and alkylators are important agents in the treatment of chronic lymphocytic leukemia (CLL)...
  71. ncbi Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program
    L Pagano
    Istituto di Semeiotica Medica, Universita Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy
    Haematologica 86:862-70. 2001
    ..To evaluate the clinical characteristics of patients with hematologic malignancies developing a filamentous fungi infection (FFI) and to define the prognostic factors for their outcome...
  72. ncbi Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton
    Sandrine Barbier
    rue de l Ecole de Medecine, 75006 Paris, France
    Haematologica 94:507-17. 2009
    ..In chronic lymphocytic leukemia, CD47 ligation induces one of these alternative forms of cell death: type III programmed cell death...
  73. ncbi Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen
    Mary Ann Weiser
    Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1179-85. 2004
    Hyperglycemia, which is not uncommon during the treatment of acute lymphocytic leukemia (ALL), has been shown to be an independent predictor of adverse outcomes among hospitalized patients with undiagnosed diabetes; it also may have the ..
  74. ncbi [Multidrug resistance in chronic lymphocytic leukemia]
    Tamás Szendrei
    Pecsi Tudomanyegyetem, Orvostudományi és Egészségtudományi Centrum I Belgyógyászati Klinika, Hematológiai Osztály, Pecs, Hungary
    Orv Hetil 149:161-7. 2008
    New prognostic factors discovered in chronic lymphocytic leukemia have recently got into the center of clinical interest...
  75. ncbi AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations
    Mona Leuenberger
    Department of Pathology, Institute of Surgical Pathology, University Hospital, CH 8091Zurich, Switzerland
    Mod Pathol 23:177-86. 2010
    The biological behavior of chronic lymphocytic leukemia and small lymphocytic lymphoma is unpredictable...
  76. ncbi Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative dis
    Wen Chi Foo
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Hum Pathol 41:1802-8. 2010
    A small fraction of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma develop Epstein-Barr virus-positive B-cell lymphoproliferative disorders...
  77. ncbi The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia
    Kourosh Lotfi
    Department of Medicine and Care, Clinical Pharmacology, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Biochem Pharmacol 71:882-90. 2006
    ..phosphorylation, which leads to activation of these prodrugs, commonly used for treatment of chronic lymphocytic leukemia (CLL)...
  78. ncbi New agents in chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 513 Lodz, Pabianicka 62, Poland
    Curr Treat Options Oncol 7:200-12. 2006
    ..have been considered the drugs of choice for first-line treatment of progressive and symptomatic chronic lymphocytic leukemia (CLL)...
  79. ncbi Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro
    J Vilpo
    Tampere University Hospital, FM2, P O Box 2000, FIN 33521 Tampere, Finland
    Haematologica 85:806-13. 2000
    ..Here we investigated whether the Ca(2+) channel blockers verapamil and nifedipine are toxic alone and in combination with P-glycoprotein-independent anticancer drugs against chronic lymphocytic leukemia (CLL) cells in vitro.
  80. ncbi Differential expression of very late activation antigen-3 (VLA-3)/VLA-4 in B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia
    L Baldini
    Department of Hematology, Centro G Marcora, Ospedale Maggiore IRCCS, Milan, Italy
    Blood 79:2688-93. 1992
    ..molecules [Leu-CAM]) in cell suspensions from the peripheral blood of 70 patients with B-cell chronic lymphocytic leukemia (B-CLL), 15 patients with leukemic lymphocytic lymphoma of intermediate differentiation (IDL), as well as ..
  81. ncbi Association between immune thrombocytopenic purpura and chronic lymphocytic leukemia in a patient carrier of anti-hepatitis C virus antibodies
    Filippo Numeroso
    Dipartimento di Medicina Intema e Scienze Biomediche, Universita degli Studi di Parma
    Ann Ital Med Int 20:197-202. 2005
    Immune thrombocytopenic purpura (ITP) occurs in 2-3% of chronic lymphocytic leukemia (CLL) patients, whereas autoimmune thrombocytopenia is very rare before the diagnosis of lymphoma...
  82. ncbi Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    Expert Rev Anticancer Ther 10:1529-43. 2010
    ..Since approval in 1997, rituximab has become the standard of care in follicular B-cell lymphoma, chronic lymphocytic leukemia (CLL) and aggressive lymphoma when combined with chemotherapy...
  83. ncbi Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 11:8413-7. 2005
    ..CD4 counts, we conducted a phase I, double-blind, placebo-controlled trial of recombinant interleukin-2 (IL-2) added to fludarabine and cyclophosphamide in patients with treatment-naive indolent lymphomas or chronic lymphocytic leukemia.
  84. ncbi Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters
    J Hulkkonen
    Department of Microbiology and Immunology, University of Tampere Medical School, Tampere, Finland
    Haematologica 85:600-6. 2000
    The growth of B-cell chronic lymphocytic leukemia (B-CLL) cells has been shown to be dependent on exogenous growth factors in vitro...
  85. ncbi Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders
    Hirotaka Nakahashi
    Department of Medicine and Clinical Science, Graduate School of Medicine, Gunma University, Gunma, Japan
    Cancer Sci 100:671-7. 2009
    The incidence of chronic lymphocytic leukemia is low in the Japanese population compared with populations in western countries, suggesting a role for genetic factors in the occurrence of this disease...
  86. ncbi Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
    Vicki A Morrison
    Section of Hematology Oncology, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    J Clin Oncol 20:3878-84. 2002
    Patients with chronic lymphocytic leukemia (CLL) may have disease transformation to non-Hodgkin's lymphoma or prolymphocytic leukemia; however, development of therapy-related acute myeloid leukemia (t-AML) is unusual...
  87. ncbi Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County
    R P Gale
    Center for Advanced Studies in Leukemia, Santa Monica, Los Angeles, CA 90049 5105, USA
    Leuk Res 24:665-9. 2000
    Chronic lymphocytic leukemia (CLL) is rare in Asians living in Asia and possibly in US Asians. In contrast, CLL is the most common leukemia in whites. The basis for this ethnic and geographic variation is unknown...
  88. ncbi Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia
    V I Avramis
    Department of Pediatrics, School of Medicine, University of Southern California, Childrens Hospital of Los Angeles 90027
    Cancer Chemother Pharmacol 24:203-10. 1989
    ..A total of 17 pediatric patients with refractory acute lymphocytic leukemia (ALL) received a continuous infusion of 5-Aza-C at 150 mg/m2 daily for 5 days after not responding to (13/..
  89. ncbi Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Poland
    Mediators Inflamm 8:277-86. 1999
    ..family cytokines-oncostatin M (OSM) and leukemia inhibitory factor (LIF)-in 63 patients with B-cell chronic lymphocytic leukemia (B-CLL) and 17 healthy controls using the enzyme-linked immunosorbent assay (ELISA) method...
  90. ncbi Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia
    Doru T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA
    Med Oncol 25:309-14. 2008
    An important biological alteration in chronic lymphocytic leukemia (CLL) is the dysregulation of immunoglobulin production, as a consequence of complex and yet incompletely understood interactions between plasma cells and the neoplastic B-..
  91. ncbi Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:695-702. 2003
    ..CpG) islands is an epigenetic modification of DNA frequently observed in adult patients with acute lymphocytic leukemia (ALL)...
  92. ncbi The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: assessment of LD50 and MTD of four ricin-based anti-cCLLa immunotoxins (ITs) in Balb/c mice
    G B Faguet
    Department of Medicine, Medical College of Georgia, VA Medical Center, Augusta 30910, USA
    Leuk Lymphoma 25:531-7. 1997
    The chronic lymphocytic leukemia (CLL) antigen (cCLLa) is a promising immunotherapy target given its disease-restricted expression, its highest prevalence among CLL surface antigens, and its lack of expression by normal T- and B-..
  93. ncbi [The value of multiparameter flow cytometry in diagnosis of lymphocytic leukemia and bone marrow involvement of non-Hodgkin's lymphoma]
    Xiao Fei Sun
    Department of Medical Oncology, Cancer Center, Sun Yet Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:1232-6. 2003
    b>Lymphocytic leukemia and bone marrow involvement of non-Hodgkin's lymphoma (NHL) can be diagnosed by bone marrow morphology or lymph node biopsy combined with bone marrow examination...
  94. ncbi [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors]
    Wei Xu
    Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
    Zhonghua Xue Ye Xue Za Zhi 30:8-12. 2009
    To investigate lipoprotein lipase (LPL) and serum thymidine kinase (TK) levels in chronic lymphocytic leukemia (CLL) and their correlations with other prognostic factors.
  95. ncbi DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine
    T Yamauchi
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Clin Cancer Res 7:3580-9. 2001
    Chronic lymphocytic leukemia (CLL) lymphocytes respond to DNA alkylation by excision repair, with the extent of repair increasing as the cells acquire resistance to alkylating agents...
  96. ncbi Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia
    Wei Xu
    Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing 210029, China
    Leuk Res 32:1071-7. 2008
    Chronic lymphocytic leukemia (CLL) is the most common adult form of leukemia in the Western world, however, infrequent in the Eastern...
  97. ncbi Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature
    Oumeish Youssef Oumeish
    Amman Clinic and the Department of Surgical Pathology Medical Laboratories, Jordan
    Int J Dermatol 45:306-10. 2006
    ..picture was consistent with diffuse, well-differentiated non-Hodgkin's lymphoma, developing into chronic lymphocytic leukemia (CLL). Endoscopy showed antral-type gastric mucosa exhibiting mild chronic gastritis...
  98. ncbi Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia
    Sona Pekova
    Institute of Hematology and Blood Transfusion, Prague, Czech RepublicInstitute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
    Mol Diagn 9:23-34. 2005
    Patients with chronic lymphocytic leukemia (CLL) can relapse even after aggressive therapy and autografts. It is commonly assumed that to prevent relapse the level of minimal residual disease (MRD) should be as low as possible...
  99. ncbi Morphological and immunophenotypic features of chronic lymphocytic leukemia
    E Matutes
    Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London, SW3 6JJ, UK
    Rev Clin Exp Hematol 4:22-47. 2000
    In this review, we summarize the morphological features and immunophenotypic profile of chronic lymphocytic leukemia (CLL) cells, discuss the value of these investigations as front line diagnostic tests, and emphasize their correlation ..
  100. ncbi Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia
    D Wolowiec
    Department of Hematology, Medical University, ul Pasteura 4, PL 50 367 Wroclaw, Poland
    Haematologica 86:1296-304. 2001
    The pathogeny of B-cell chronic lymphocytic leukemia (B-CLL) involves both deregulated proliferation and inhibition of cell death...
  101. ncbi Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro
    Kanagasabai Ganeshaguru
    Department of Hematology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    Haematologica 87:167-76. 2002
    ..In addition to its growth inhibitory properties, PKC412 reverses the efflux function of the multidrug resistance (MDR)-1 gene product, P-glycoprotein (P-gp)...

Research Grants85

  1. Post-transplant vaccines to enhance graft-versus-leukemia responses
    CATHERINE JU YING WU; Fiscal Year: 2010
    ..the parent clinical trial to this proposal, we immunize post-allo-HSCT patients who have advanced chronic lymphocytic leukemia (CLL) with a vaccine consisting of irradiated autologous leukemia cells together with irradiated bystander ..
  2. Long-term Effects of Occupational Radiation Exposures
    David Richardson; Fiscal Year: 2009
    ..particularly on slow-progressing malignant diseases, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The proposed analyses will commence with evaluation of time-since- exposure as a temporal modifier of ..
  3. ADENINE DEOXYNUCLEOTIDE METABOLISM AND IMMUNE FUNCTION
    Dennis Carson; Fiscal Year: 1993
    ..remissions in more than 70% of patients with hairy cell leukemia, and has excellent activity in chronic lymphocytic leukemia, and lymphoma...
  4. Long-term Effects of Occupational Radiation Exposures
    David B Richardson; Fiscal Year: 2010
    ..particularly on slow-progressing malignant diseases, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The proposed analyses will commence with evaluation of time-since- exposure as a temporal modifier of ..
  5. Preclinical Diagnostic Imaging of Amyloid
    Jonathan S Wall; Fiscal Year: 2010
    ..non-cerebral) amyloid diseases in the USA, is estimated to be ~ 5300 per yr which exceeds that for acute lymphocytic leukemia (~ 4,000 per yr)...
  6. Preclinical Diagnostic Imaging of Amyloid
    Jonathan Wall; Fiscal Year: 2009
    ..non-cerebral) amyloid diseases in the USA, is estimated to be ~ 5300 per yr which exceeds that for acute lymphocytic leukemia (~ 4,000 per yr)...
  7. HUMAN IL3 ACTIVATION OF PROTEIN KINASE C AND BCL-2 GENE
    Yufang Shi; Fiscal Year: 2001
    ..a crucial role in the development of early hematopoietic progenitor cells and a role in some forms of acute lymphocytic leukemia. In order to understand the mechanism of action of IL-3 in normal human hematopoiesis as well as in ..
  8. Assays for Screening Histone Modifications in Cancer
    Michael A Freitas; Fiscal Year: 2010
    ..and their post-translational modifications on the development, progression and treatment of chronic lymphocytic leukemia (CLL), we intend to develop and apply high mass accuracy mass spectrometry based assays to profile CLL-..
  9. Modulation of Glucocorticoid-Evoked Lymphocyte Apoptosis by BTG1
    RHEEM MEDH; Fiscal Year: 2007
    ..Using a pair of human T lymphocytic leukemia sister cell lines, CEM-C-14 and CEM-C1-15, which are sensitive and resistant, respectively to GC-evoked ..
  10. Genomic Complexity and Clinical Outcome in Chronic Lymphocytic Leukemia
    SAMI NIMER MALEK; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and has a highly variable clinical course...
  11. Validation of RNA and DNA Biomarkers of Prognosis in Chronic Lymphocytic Leukemia
    Lynne Abruzzo; Fiscal Year: 2007
    Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western Hemisphere. Although it has been viewed as an indolent disease of older adults, its clinical course is heterogeneous and difficult to predict...
  12. Micro RNA Expression and Cancer
    Thomas Schmittgen; Fiscal Year: 2005
    ..two human miRNAs (miR15 and miR16) have been mapped to a region (13q14) that is commonly deleted in chronic lymphocytic leukemia (CLL)...
  13. Origin of CD5+ B cell Lymphoma/Leukemia in Mice
    Kyoko Hayakawa; Fiscal Year: 2010
    B CLL (B cell chronic lymphocytic leukemia) in humans is a slow accumulative disease of CD5+ B cells that develops in the elderly population, accounting for a third of adult leukemia cases in the United States and Western Europe...
  14. Genetic Epidemiology of Chronic Lymphocytic Leukemia
    Nicola J Camp; Fiscal Year: 2010
    Chronic Lymphocytic Leukemia (CLL) is a B-cell lymphoproliferative disorder primarily involving the bone marrow, blood and lymph nodes...
  15. Role of the BCR in B Cell Chronic Lymphocytic Leukemia
    Diane Jelinek; Fiscal Year: 2009
    B cell chronic lymphocytic leukemia (B-CLL) is the most common form of leukemia among older adults in Western countries and is a significant cause of morbidity and mortality in the older adult population...
  16. Role of the BCR in B Cell Chronic Lymphocytic Leukemia
    Diane F Jelinek; Fiscal Year: 2010
    B cell chronic lymphocytic leukemia (B-CLL) is the most common form of leukemia among older adults in Western countries and is a significant cause of morbidity and mortality in the older adult population...
  17. Phase I study of 5-aza-2?-deoxycitidine in acute lymphocytic leukemia
    Guillermo Garcia Manero; Fiscal Year: 2007
    The prognosis of patients with relapsed or refractory acute lymphocytic leukemia (ALL) is extremely poor and it has not changed over the last decade...
  18. Predictors of Adult Leukemia
    Julie Ross; Fiscal Year: 2009
    ..Due to a concurrent study of chronic lymphocytic leukemia (CLL) in southern Minnesota, we will focus this study on myeloid leukemia including acute myeloid leukemia (..
  19. Combination Therapy in B-Chronic Lymphocytic Leukemia
    Neil Kay; Fiscal Year: 2009
    ..PUBLIC HEALTH RELEVANCE: Chronic Lymphocytic Leukemia is a very common leukemia in this country and is currently incurable...
  20. Combination Therapy in B-Chronic Lymphocytic Leukemia
    Neil E Kay; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Chronic Lymphocytic Leukemia is a very common leukemia in this country and is currently incurable...
  21. Experimental Therapeutics in Acute Leukemias
    William Blum; Fiscal Year: 2007
    ..phase I clinical study using this dosing strategy administered weekly in patients with refractory chronic lymphocytic leukemia (CLL) demonstrated impressive clinical responses...
  22. MicroRNA Cellular Functions and Target Identification in Acute Myeloid Leukemia
    Elizabeth Mambo; Fiscal Year: 2006
    ..as microRNAs (miRNAs) have been implicated in various types of cancer including lung, breast and chronic lymphocytic leukemia (CLL)...
  23. RhoH GTPase in Hematopoiesis and Cancer
    David A Williams; Fiscal Year: 2010
    ..Since ZAP-70 is a prognostic indicator in chronic lymphocytic leukemia (CLL), we hypothesized that RhoH function may be critical in CLL cell behavior...